Repligen Corporation
$ 165.76
-0.46%
04 Dec - close price
- Market Cap 9,330,755,000 USD
- Current Price $ 165.76
- High / Low $ 167.67 / 161.67
- Stock P/E 8290.00
- Book Value 37.01
- EPS 0.02
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE N/A %
- 52 Week High 182.52
- 52 Week Low 102.97
About
Repligen Corporation, headquartered in Waltham, Massachusetts, is a leading provider of bioprocessing technologies and systems that enhance the development and manufacturing of biologic drugs. The company's innovative solutions, which span from upstream to downstream processes, are utilized by biopharmaceutical companies worldwide, including in North America, Europe, and Asia Pacific. With a focus on high-quality products and ongoing innovation, Repligen is well-positioned to capitalize on the growing demand for biologics, driven by advancements in therapeutics and increased investment in the biopharmaceutical sector.
Analyst Target Price
$187.56
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-07-29 | 2025-04-29 | 2025-02-19 | 2024-11-12 | 2024-07-30 | 2024-05-01 | 2024-02-21 | 2023-10-31 | 2023-08-02 | 2023-05-02 | 2023-02-22 |
| Reported EPS | 0.46 | 0.37 | 0.39 | 0.44 | -0.0117 | 0.33 | 0.28 | 0.33 | 0.23 | 0.53 | 0.64 | 0.68 |
| Estimated EPS | 0.4137 | 0.39 | 0.3668 | 0.4191 | 0.33 | 0.33 | 0.3 | 0.33 | 0.17 | 0.48 | 0.59 | 0.58 |
| Surprise | 0.0463 | -0.02 | 0.0232 | 0.0209 | -0.3417 | 0 | -0.02 | 0 | 0.06 | 0.05 | 0.05 | 0.1 |
| Surprise Percentage | 11.1917% | -5.1282% | 6.325% | 4.9869% | -103.5455% | 0% | -6.6667% | 0% | 35.2941% | 10.4167% | 8.4746% | 17.2414% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RGEN
2025-10-25 03:02:11
Repligen (RGEN) is expected to report a year-over-year decline in Q3 2025 earnings despite higher revenues. Wall Street anticipates earnings of $0.42 per share, down 2.3%, on revenues of $181.23 million, up 17%. The company currently holds a Zacks Rank of #4 and a negative Earnings ESP of -1.54%, making a positive earnings surprise less likely.
2025-10-25 03:02:11
The article content displays a "403 Forbidden" error, indicating access to the requested page is denied. This typically means the user is not authorized to view the resource and the server is refusing to fulfill the request. The server gateway is identified as Microsoft-Azure-Application-Gateway/v2.
2025-10-15 11:30:00
Repligen Corporation announced it will report its third quarter 2025 financial results on Tuesday, October 28, 2025, before the market opens. The company will host a conference call at 8:30 a.m. ET to discuss these results and business updates for the period ending September 30, 2025. Repligen specializes in bioprocessing technologies for biological drug manufacturing.
2025-10-15 11:30:00
Repligen Corporation (NASDAQ: RGEN) announced it will report its third quarter 2025 financial results on Tuesday, October 28, 2025. A press release will be issued before market open, followed by a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine-month periods ended September 30, 2025. The conference call will be accessible via toll-free numbers and a webcast available on the company's Investor Relations website.
2025-10-14 19:43:32
This article indicates an error occurred while loading content from Investing.com regarding Repligen's Q2 2025 earnings call. Despite the anticipated revenue growth and stock dip, the full earnings call transcript and details are currently unavailable due to a client-side exception.
2024-12-09 12:41:00
Repligen Corporation has launched its AVIPure® dsRNA Clear OPUS® columns to improve the production of mRNA therapeutics and vaccines. This new solution efficiently removes double-stranded RNA (dsRNA) impurities using proprietary affinity ligands and Tantti's DuloCore® bead technology, significantly enhancing drug efficacy and reducing immune responses. The pre-packed columns are designed for seamless integration into existing biomanufacturing workflows, offering a scalable and cost-effective purification method.
